ZURA
Zura Bio Limited Class A Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$502.87M
P/E Ratio
—
EPS
$-1.06
Beta
0.24
52W High
$7.44
52W Low
$0.98
50-Day MA
$6.08
200-Day MA
$4.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited (Ticker: ZURA) is a forward-thinking biotechnology company focused on developing transformative therapies for autoimmune disorders and rare diseases. The company is poised for growth with a robust pipeline of innovative drug candidates, underscored by its commitment to rigorous clinical trials and cutting-edge research methodologies. Guided by an experienced management team and bolstered by strategic partnerships, Zura Bio is strategically positioned within the biopharmaceutical sector, presenting significant opportunities for institutional investors seeking exposure to advanced therapeutic solutions in an evolving marketplace.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-75.20M |
| Operating Margin | 0.00% |
| Return on Equity | -52.50% |
| Return on Assets | -32.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.38 |
| Price-to-Book | 4.95 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $94.88M |
| Float | $54.74M |
| % Insiders | 21.12% |
| % Institutions | 56.45% |
Historical Volatility
HV 10-Day
66.16%
HV 20-Day
53.35%
HV 30-Day
66.42%
HV 60-Day
66.26%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
1
Strong Buy6
BuyData last updated: 4/29/2026